An observational study in Childhood ALL, sponsored by French Africa Pediatric Oncology Group. Recruiting at 3 sites in 3 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by French Africa Pediatric Oncology Group · Observational
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
A few studies conducted in developing countries confirm that it is possible to significantly improve the prognosis of children with Acute Lymphoblastic Leukemia (ALL) provided that the centres can benefit from a precise and adapted protocol and logistical support.
The GFAOP has been working with units for the past 20 years and this is the second study put in place by the group for the treatment of LAL. The initial study was a feasibility study with the treatment of standard risk LAL. This study GFALAL2019 aims to include both standard and high-risk forms of LAL.
With this study it is hoped to:
0 to 18 years of age presenting for treatment in any of the unit selected to carry out the recommandations
Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
-
Exclusion Criteria:
ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Feasibility of these recommendations
Availability of drugs. This is part of the project as we are working with Low or low to Middle Income countries.
Time frame: This can be initially reviewed after the first 2 years and will be evaluated at the end for the community.
Correct application of therapeutic recommendations
Availability of drugs and adherence to protocol: Some centers may at times have to find locally the chemiotherapy for application of the protocol. The capacity of the units to do this is alos being studied. By looking at why treatment was not given. Was it because of lack of discipline regarding the attendance at the units for treatment, transport, accommodation, or medication not available ?
Time frame: 5 weeks
Complete Remission Rate (CR) close to 85% after induction
Evaluation of the CR j34 or J42 depending on the risk level High or standard.
Time frame: J 34 or j42 post start of induction treatment for all children studied.
Ability to follow treatment:
The number of children who stop treatment without the consent of the doctor.
Time frame: 5 weeks
Outcome
The vital status at the end of the first line of treatment.
Time frame: 5 years
Survival without relapse of patients
the number of children in complete remission without relapse at the end of treatment .
Time frame: first evaluation starts in 2026 so that enough time has elapsed to evaluate.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma→
French Africa Pediatric Oncology Group